Aclaris Therapeutics, Inc. (0H8T.L) LSE

4.62

+0.095(+2.10%)

Updated at June 02 06:54PM

Currency In USD

Valuation

Market Cap366.47M
Enterprise Value350.19M
P/E Ratio-8.56
PEG Ratio-0.16
Price/Sales Ratio66.73
Price/Book Ratio4.15
Enterprise/Revenue63.54
Enterprise/EBITDA-7.28

Fiscal Year

Fiscal YearDecember 31, 2025
Most Recent QuarterMarch 31, 2026

Profitability

Profit Margin-8.33
Operating Margin-9.62

Management Effectiveness

Return On Assets-0.35
Return On Equity-0.56

Income Statement

Revenue7.83M
Revenue/Share0.06
Gross Profit542,000
EBITDA-73.42M
Net Income-64.92M
Diluted EPS-0.53

Balance Sheet

Total Cash105.42M
Total Cash/Share0.82
Total Debt1.99M
Total Debt/Equity0.01
Current Ratio4.03
Book Value Per Share1.12

Price History

52-Week Change216.44
52-Week High10.87
52-Week Low0.61
Moving Average 50 Days1.2
Moving Average 200 Days4.31

Statistics

Average Volume12,279
Shares Outstanding124.88M
% Held by InstitutionsN/A

Dividend And Splits

Trailing Annual Dividend Rate0
Trailing Annual Dividend Yield0
Payout Ratio0
Last Split FactorN/A
Last Split DateN/A